The studies provided 3278 patient-years of exposure to BIL and 2016 patient-years of exposure to comparator insulins in three patient groups: type 1 diabetes, type 2 diabetes on a basal-bolus regimen, and type 2 diabetes on basal insulin only. The gene discussed is INS; the disease is type 2 diabetes mellitus.